Qingdao Pangu Robotics Completes Series A Funding to Accelerate Integrated R&D, Manufacturing, and Sales of Medical Education Products

The company’s product portfolio encompasses medical robots, surgical simulators, software, and curricula, primarily designed for the training of physicians, nurses, medical students, pre-hospital emergency care providers, and other healthcare professionals. By establishing strategic partnerships with leading global companies in medical simulation, the company integrates and leverages advanced international technologies to enhance the quality of medical training and improve patient safety. To date, the company has collaborated with numerous medical institutions and medical educators both domestically and internationally, delivering comprehensive product solutions and design services for simulation training centers that align with modern medical education principles.

Pangu Robotics has consistently adhered to the product philosophy of “technology introduction and independent development.” The company’s product portfolio comprises high-fidelity patient simulators, surgical simulation systems, ultrasound simulators, simulated medical equipment, general-purpose training models, practical training center management systems, and virtual reality solutions. It provides comprehensive and efficient simulation-based training solutions for medical schools, hospitals, and national defense forces.

The Company has established collaborations with domestic and international professional medical education associations, as well as numerous top-tier hospitals, to introduce international medical education resources from the Society for Simulation in Healthcare (SSH), the Association of Standardized Patient Educators (ASPE), Brigham and Women’s Hospital (BWH) affiliated with Harvard Medical School, Cedars-Sinai Medical Center, and Boston Children’s Hospital to Chinese medical schools and hospitals. It is committed to building a shared resource ecosystem encompassing domestic and international medical education resources and technologies.

Core Competencies of the Company: Pangu Robotics stands as an industry leader in technology, distribution channels, resources, and team capabilities. Specifically:

● Polymer materials, product manufacturing processes, physiology-driven technologies, and multiple utility model invention patents;

● With 20 years of experience in the medical simulation industry, possessing established channels with leading distributors and end-users within the field;

● Disruptive business models in the domestic and international markets;

● The heads and key members of the R&D, marketing, and academic teams have all been engaged in the simulation medicine industry for many years;

● Provide turnkey training solutions for users.

■ Blue Phantom Ultrasound Model Series Products;

■ Products used for skills training in medical schools, hospitals, the military, and other institutions;

■ Robotic simulated patients and surgical simulators;

Ren Cheng, CEO of Pangu Robotics“Securing this financing is merely a new starting point. We will continue to strive for excellence and drive innovation to create greater value for our investors, users, and team members. We extend our gratitude to the investors for their trust and support. Their investment represents not only an endorsement of our achievements but also confidence in our future growth. At the same time, I wish to thank every member of our team. Your unity, collaborative spirit, willingness to innovate, and relentless efforts have earned us the favor of investors. Today’s success is a victory for each and every one of you, and I am proud to work alongside you.”

Zhou Shengyun, Partner at Dayou Capitalstated: “A successful financing round is more than just a number; it represents our confidence and expectations for this project. Pangu Robot’s series of innovations in products, technology, and business model will largely change the rules of the game in both the domestic and international markets of this industry. We firmly believe that Pangu Robot will reshape the industry landscape within the next 3–5 years, delivering genuine value to users.”

Qingdao Jinshui Group Co., Ltd. is one of the state-owned enterprises directly under the Licang District Government, with a registered capital of RMB 2 billion and an issuer credit rating of AA+. The Group currently operates five core business segments: urban operations, asset management, financial investment, domestic and international trade, and cultural tourism. Its subsidiary, Qingdao Jinshui Investment Holding Co., Ltd., was established in January 2017 with a registered capital of RMB 2.5 billion, and has made in-depth investments in high-end equipment manufacturing industries such as aerospace, biopharmaceuticals, national defense and military industry, and new materials. The company holds various financial licenses, including private equity funds, private securities funds, financial leasing, and commercial factoring.

Qingdao Dayou Private Equity Fund Management Co., Ltd. is a professional venture capital investment management firm that focuses on high-growth, innovative small and medium-sized enterprises in the ICT and big health sectors. Its main promoters all have more than 10 years of experience in capital markets, industrial operations, and investment management. The company currently manages 16 funds and has completed investments in numerous high-quality companies, including Chipsea Technologies (688595), Longhua New Materials (301149), Hongyun Biotech, Yaoxin Biotech, Qingyun Ruijing, Lizi Optoelectronics, Lorentz, Advchip Electronics, Chaoxinxing, and Xingyuan Borui, serving as a key early-stage investor for many of these enterprises.